Compare Bilibili Inc (BILI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Novo Nordisk A/S — how do they compare? Bilibili Inc trades at $17.6 (market cap $7.65B), while Novo Nordisk A/S trades at $46.4 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 27.2× Bilibili Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BILI | NVO | |
|---|---|---|
Market Cap | $7.65B | $207.85B |
Sector | Media | Health |
52-Week High | $35.92 | $63.98 |
52-Week Low | $15.96 | $35.29 |
Enterprise Value | $5.49B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.61, down 7.27% over 24 hours, reflecting bearish technical signals despite strong analyst support. The company reported Q1 2026 EPS of $0.19, beating expectations, with revenue growth projected to $30.8B in 2026. Profit margins improved to 4.58%, though valuation ratios like P/E of 36.24 remain elevated. Recent news highlights a $300 million share repurchase program and upcoming Q2 earnings on August 27, 2026.
The outlook is mixed: bullish fundamentals from earnings beats and buy-side consensus contrast with near-term technical weakness. Key opportunities include user monetization and AI integration, while risks involve competitive pressure and reliance on Chinese market dynamics. The stock's trajectory hinges on Q2 results delivering sustained margin expansion.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
